

Yann-Alexandre Vano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6897972/publications.pdf>

Version: 2024-02-01

26
papers

1,435
citations

516710

16
h-index

501196

28
g-index

30
all docs

30
docs citations

30
times ranked

2565
citing authors

#	ARTICLE	IF	CITATIONS
1	Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. , 2022, 10, e004316.		45
2	Nivolumab, nivolumab+ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Lancet Oncology, The, 2022, 23, 612-624.	10.7	66
3	Future treatment options in metastatic clear cell renal cell carcinoma. Bulletin Du Cancer, 2022, 109, 2S47-2S58.	1.6	0
4	MtTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights. International Journal of Molecular Sciences, 2022, 23, 7649.	4.1	10
5	Update on the most promising biomarkers of response to immune checkpoint inhibitors in clear cell renal cell carcinoma. World Journal of Urology, 2021, 39, 1377-1385.	2.2	15
6	Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC). Cancers, 2021, 13, 231.	3.7	42
7	First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?. Cancers, 2021, 13, 5548.	3.7	11
8	Open-label phase II to evaluate the efficacy of NEOadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO. Bulletin Du Cancer, 2020, 107, eS8-eS15.	1.6	11
9	BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer. Bulletin Du Cancer, 2020, 107, eS22-eS27.	1.6	37
10	Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. Cancers, 2020, 12, 1673.	3.7	13
11	NIVOREN GETUG-AFU 26 translational study: Association of PD-1, AXL, and PBRM-1 with outcomes in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N).. Journal of Clinical Oncology, 2020, 38, 618-618.	1.6	8
12	Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors. Clinical Genitourinary Cancer, 2019, 17, e981-e994.	1.9	34
13	Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. European Journal of Cancer, 2019, 108, 33-40.	2.8	96
14	PD-L1 Expression and CD8+ T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer. European Urology Focus, 2019, 5, 192-196.	3.1	81
15	Immune-based identification of cancer patients at high risk of progression. Current Opinion in Immunology, 2018, 51, 97-102.	5.5	29
16	Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients. PLoS ONE, 2018, 13, e0195042.	2.5	57
17	Immune checkpoint inhibitors myocarditis: not all cases are clinically patent. European Heart Journal, 2018, 39, 3553.	2.2	21
18	Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2017, 15, 350-355.	1.9	26

#	ARTICLE	IF	CITATIONS
19	Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 4416-4428.	7.0	252
20	Sunitinib in kidney cancer: 10 years of experience and development. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 129-142.	2.4	30
21	Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals. <i>European Journal of Cancer</i> , 2016, 66, 75-82.	2.8	5
22	Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). <i>OncImmunology</i> , 2015, 4, e1049804.	4.6	51
23	Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3031-3040.	7.0	355
24	The immune response in cancer: from immunology to pathology to immunotherapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 467, 127-135.	2.8	51
25	Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 523-542.	2.4	11
26	Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib. <i>BJU International</i> , 2014, 114, 81-89.	2.5	68